Central Line-Associated Bloodstream Infection (CLABSI)

Central line-associated bloodstream infection (CLABSI) is a serious, potentially life-threatening healthcare-associated infection. It is defined as the recovery of a recognized pathogen from a blood culture of a patient who currently has a central line or had one within the 48 hours before the onset of the infection.

Importantly, CLABSI is a surveillance definition used by public health organizations, such as the Centers for Disease Control and Prevention (CDC), to track rates of infection in institutions. A CLABSI is different than a strictly clinical diagnosis of a catheter-related bloodstream infection (CRBSI) in which the definitive laboratory evidence must show that the catheter hub or tip is the exact source of the bacteremia. A CLABSI only requires that the bloodstream infection be primary and that there be no other identifiable secondary source of infection anywhere else in the body.

Epidemiology and Incidence of Central Line-Associated Bloodstream Infection (CLABSI) in Healthcare Settings

The epidemiology of CLABSI varies widely across clinical and socioeconomic settings. In high-income countries, the strict application of quality improvement measures has led to infection rates from 0.5 to 2.2 per 1,000 catheter-days. On the other hand, LMICs are suffering from a much higher burden, with incidence densities of 3.5 to 17.04 infections per 1,000 catheter-days in resource-constrained units.

The highest incidence is in hospital ICUs, including neonatal, pediatric, and adult surgical/medical ICUs, due to the massive number of invasive procedures, emergency catheterizations, and multilumen line configurations. While general trends had been declining globally for ten years, the COVID-19 pandemic significantly interrupted normal infection prevention protocols, leading to a sharp, widespread increase in CLABSI rates due to overextended staff-to-patient ratios and altered maintenance frequencies.

Causes and Pathogenesis of Central Line-Associated Bloodstream Infection (CLABSI)

The pathogenesis of CLABSI involves the colonization of the intravascular device by microorganisms, which subsequently gain direct access to the bloodstream.

This process occurs primarily through four distinct pathways:

• Extraluminal Migration: Usually seen within the first 7-10 days after catheter placement. Skin flora from the insertion site travels down the outer surface of the catheter track.
• Intraluminal Contamination: It is frequently seen in long-term lines (more than 10 days) when microbes enter the lumen of the catheter from outside through the injection hubs, injection ports, or contaminated connections, mostly introduced by the hands of health care workers.
• Hematogenous Seeding: Microorganisms in the bloodstream from a distant focus of infection are able to attach to the catheter surface.
• Infusate Contamination – Occasionally, the intravenous fluids, medications, or total parenteral nutrition (TPN) are contaminated during manufacturing or preparation.

Risk Factors for Central Line-Associated Bloodstream Infection (CLABSI)

Risk factors can be seen according to device-specific characteristics and patient-centered conditions that are shown below:

Device and Procedural Factors

• Anatomical Site: The femoral vein has the highest risk of colonization and subsequent infection due to its proximity to skin folds and perineal flora; the internal jugular vein has an intermediate risk, while the subclavian vein has the lowest risk.
• Catheter Duration: The longer the central line is in place, the higher the risk.
• Number of Lumens: Multi-lumen catheters significantly increase the frequency of hub manipulation and physical entry points, increasing exposure risks compared to single-lumen lines.
• Urgency of insertion: Lines inserted during emergency or bedside resuscitation, where standard maximum sterile barrier precautions are bypassed, are at much higher risk.

Patient Factors

• Chronic diseases such as diabetes mellitus, chronic kidney disease (CKD), and severe malnutrition have a profound effect on the structural and immune defenses
• Immune Status: Severe neutropenia, active malignancies, and immunosuppressive medications severely impair the body’s natural ability to clear microorganisms.
• Infusate Type: TPN or lipid formulations provide a huge growth medium for some pathogens, particularly fungi.

Central Line-Associated Bloodstream Infection (CLABSI) Common Pathogens

The microbiologic composition of CLABSI includes Gram-positive and Gram-negative organisms and fungi. The exact composition is determined by local patterns of institutional resistance and regional context.

Clinical Features of Central Line-Associated Bloodstream Infection (CLABSI)

The clinical features of CLABSI range from subtle, localized signs to overwhelming systemic shock.

Systemic Manifestations: The most frequent clinical trigger is the sudden onset of fever and rigors or chills without an apparent alternate cause. 

• Fever may be absent in the elderly or immunocompromised
• Hypothermia, 
• Unexplained tachypnea, 
• Altered mental status, or 
• Sudden, unprovoked hypotension may be present. 

Local Signs: The catheter exit site may be examined for 

• Localized erythema (redness), 
• Induration (firmness), 
• Warmth, 
• Tenderness, or 
• Purulent drainage.

It’s important to note that while the external insertion site of the central line may look perfectly normal, the line itself can be the source of systemic sepsis.

Central Line-Associated Bloodstream Infection (CLABSI) Diagnosis 

An accurate diagnosis requires paired clinical observations and precise microbiological testing before the initiation of definitive antimicrobial laboratory norms to meet surveillance criteria for it. A primary bloodstream infection must have one or more blood cultures positive for a recognized pathogen. If the isolated organism is a common skin commensal (e.g., coagulase-negative staphylococci), it must be isolated from two or more independent blood cultures on separate occasions to rule out simple sample contamination.

Clinical Diagnosis Method

To prove the catheter is the primary driver, clinicians utilize peripheral blood drawings that are from peripheral veins and catheter hubs.

Equal volumes of blood are inoculated into blood culture bottles, one from a peripheral vein and one from an indwelling catheter hub. A positive culture from the catheter at least 2 hours before the peripheral culture strongly suggests the catheter as a source of infection because there is a significantly higher bacterial burden within the line.

Management and Treatments of Central Line-Associated Bloodstream Infection (CLABSI)

Once suspected or confirmed, the following treatments were provided:

Empirical therapy must be broad enough to cover both Gram-positive and Gram-negative organisms and should be tailored based on local antibiograms.

• Gram-Positive treatment: Intravenous vancomycin continues to be the first-line standard for suspected methicillin-resistant Staphylococcus aureus (MRSA) and coagulase-negative staphylococci.
• Gram-Negative treatment: Broad-spectrum agents with antipseudomonal activity (e.g., Cefepime, Piperacillin-Tazobactam) or a carbapenem (Meropenem) is used, especially in critically ill or neutropenic patients.
• Antifungal treatment: Empiric echinocandins (e.g., caspofungin) are added if the patient is high risk for candidemia (long-term TPN, profound immunosuppression, or prolonged broad-spectrum antibiotic use).

Once specific pathogens or microorganisms are identified and antibiotic sensitivities are confirmed, therapy must be narrowed to targeted definitive agents to limit the development of multidrug-resistant strains.

Catheter Removal Criteria

If the CLABSI is complicated or due to high-virulence, biofilm-heavy pathogens, the catheter should be removed promptly. Line removal is definitely indicated if:

• Severe sepsis, hemodynamic instability, or septic shock.
• Persistent bacteremia (positive blood cultures continuing beyond 72 hours of appropriate antibiotic therapy).
• Infections caused by Staphylococcus aureus, Pseudomonas aeruginosa, Bacillus species, Candida species, or other mycobacteria.
• Evidence of secondary complications such as endocarditis or septic thrombophlebitis.

Catheter Retention and Antibiotic Lock Therapy

In very selected cases of uncomplicated CLABSI (e.g., coagulase-negative staphylococci), when vascular access is extremely limited or replacement carries a significant mechanical risk, line retention may be attempted.

In such cases, systemic therapy should be supplemented with Antibiotic Lock Therapy (ALT). This method consists of instilling a highly concentrated solution of an antibiotic combined with an anticoagulant (e.g., heparin) into the catheter lumen during times when the line is not in use. The solution is left to “lock” the lumen, achieving concentrations of the drug thousands of times higher than can be safely achieved in systemic circulation, effectively penetrating and dissolving the bacterial biofilm.

Complications and Outcomes of Central Line-Associated Bloodstream Infection (CLABSI)

If CLABSI is not treated promptly, it can lead to serious complications, from local to systemic sequelae.

• Pathogens that cause infective endocarditis are shed from the biofilm matrix and seed the heart valves. Long-term intravenous therapy or surgical valve replacement is required.
• Septic Thrombophlebitis: A blood clot that is infected and develops in the vein near the catheter tip and is a continuous source of infection throughout the body.
• Metastatic infections: Hematogenous seeding may lead to osteomyelitis, septic arthritis, or splenic/hepatic abscesses.
• Healthcare costs are expensive.
• Death.

Prevention and infection control strategies for Central Line-Associated Bloodstream Infection (CLABSI)

Since most CLABSIs can be prevented, current hospital practice is based on rigorous and standardized protocols, which are divided into two operational phases.

Best Practices of Insertion

• Hand hygiene: Wash hands thoroughly with soap and water or alcohol-based rubs before touching any part of the line.
• Maximal sterile barrier precautions: The inserter must wear a sterile gown, sterile gloves, a cap, and a mask, and the patient must be completely covered with a full-body sterile drape during the procedure.
• Skin Antisepsis: Prepare the insertion site with a 2% chlorhexidine gluconate solution in 70% isopropyl alcohol and leave to air-dry completely for maximum residual kill activity.
• Site Selection: Non-tunneled lines should preferentially be placed in the subclavian vein rather than the internal jugular or femoral veins when possible to decrease the background bacterial density.

Maintenance Best Practice

• Hub cleaning: Actively clean all injection ports and catheter hubs with an alcohol or chlorhexidine wipe using mechanical friction for a minimum of 10 to 15 seconds before each access event every day.
• Daily Medical Necessity Review: Clinicians and nursing teams must audit the line every single day, prompting the immediate removal of any central venous catheter as soon as it is no longer strictly required for active care.

Advantages of Prevention Bundles and Limitations in CLABSI Control

Advantages of Prevention in CLABSI Control

When standard insertion and maintenance bundles are mandated, compliance is easily audited via checklist tracking. This systematic approach creates an institutional culture of accountability, driving down infection rates significantly, even in highly complex critical care environments.

Limitations of CLABSI Control Strategies

Despite the proven efficacy of bundles, healthcare networks face ongoing operational hurdles:

• Sustainability and Fatigue: Maintaining 100% compliance with complex checklists over time can cause clinician fatigue, and compliance rates frequently drop during severe staff shortages or regional health crises.
• High-Risk Patient Groups: Certain patient populations, such as extremely low-birthweight neonates or pediatric oncology patients with long-term, indwelling vascular lines, exhibit persistent infection rates despite flawless bundle compliance, signaling a clear need for advanced adjunctive strategies like antimicrobial lock protocols.

Guidelines and Protocols for CLABSI Prevention (CDC, WHO)

International recommendations from the Centers for Disease Control and Prevention (CDC), the Healthcare Infection Control Practices Advisory Committee (HICPAC), and the World Health Organization (WHO) advise structured institutional oversight:

• The CDC/NHSN Protocol: Defines standard surveillance methodologies to track institutional performance via the Standardized Infection Ratio (SIR), allowing hospitals to benchmark their infection rates against national averages.
• Updated joint SHEA/IDSA practices agree on the use of chlorhexidine-impregnated dressings for central lines in adult and pediatric populations, strict adherence to specialized hub-disinfection caps, and structured education and competency assessments for all staff members tasked with inserting or maintaining intravascular access lines.

Conclusion

Central line-associated bloodstream infections remain a major high-cost threat to patient safety in critical care medicine. Although the pathogenesis of these infections is dependent on rapid formation of protective biofilms on indwelling materials, clinical studies demonstrate that the vast majority of these infections are preventable. Going forward, elimination of CLABSI is dependent on absolute, unyielding compliance with insertion and maintenance bundles, immediate removal of redundant access points, and the tailored deployment of next-generation strategies like antimicrobial locks to protect our most vulnerable patient populations.

References

1. El-Sokkary, R., Negm, E., ElNaser, F., Soliman, A., Afifi, A., Morsi, S., Abdel-Kareem, A., Eladl, A., Ibrahim, M., Abdeldayem, M., & Malek, M. (2025, 12 12). Central venous catheter care and the healthcare–environment interface: outcomes of a quality improvement initiative in a resource-constrained ICU. Frontiers in Public Health, 13(1713370). 10.3389/fpubh.2025.1713370
2. Ghimire, R. (2025, December 7). Predictors of Central Line Associated Blood Stream Infections (CLABSI) among patients admitted in Intensive Care Unit of a tertiary care center. Journal of General Medicine of Nepal, 199-204. 10.3126/jgmc-n.v18i2.85869
3. Haddadin, Y. (2022, 11 26). Central line-associated bloodstream infections. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK430891
4. L’Etoile, N., Li, Y., Hayes, E., & Coffin, S. E. (2026, February 6). Antimicrobial locks for the prevention of central line associated bloodstream infections in pediatric patients: a systematic review and network meta-analysis. Antimicrobial Resistance & Infection Control, 15(1), 34. 10.1186/s13756-026-01704-z
5. Rajandra, A., Yunos, N. M., Teo, C. H., Kukreja, A., Suhaimi, N. A., Razali, S. Z. M., Basri, S., Ju Teh, C. S., Leong, C. L., Ismail, I., Azmel, A., Yunus, N. H. M., Rajahram, G. S., Ismail, A. J., Deva, S. R., Kee, P. W., Group, T. W., & Ponnampalavanar, S. S. L. S. (2025, March 7). Incidence, Compliance, and Risk Factor Associated with Central Line-Associated Bloodstream Infection (CLABSI) in Intensive Care Unit (ICU) Patients: A Multicenter Study in an Upper Middle-Income Country. BMC Infectious Diseases, 14(3), 271. 10.3390/antibiotics14030271
6. Rhodes, K. A., & Youree, B. (2025, January 29). A multidisciplinary approach to reducing central line-associated bloodstream infections (CLABSI). Open Forum Infectious Diseases, 12(1). 10.1093/ofid/ofae631.432
7. Sheet, N. F. (2026, January). National Healthcare Safety Network (NHSN) Overview. Centers for Disease Control and Prevention, 1-7. https://www.cdc.gov/nhsn/pdfs/pscmanual/1psc_overviewcurrent.pdf
8. Sleziak, J., Blazejewska, M., & Duszynska, W. (2025, August 10). Central Line-Associated Bloodstream Infections in Intensive Care Unit During and After the COVID-19 Pandemic, 5-Year Prospective Observational Study. PubMed. https://doi.org/10.3390/jcm14165655
9. Verma, P., Gupta, S., Bansal, S., & Pandey, G. P. (2026, February 6). Surveillance of central-line-associated blood stream infections (CLABSI) in intensive care units of a tertiary care center in Western India. GMS Hyg Infect Control. 10.3205/dgkh000618